Newsletter | September 9, 2026

09.09.26 -- Five Of The Most Useful Transformations In Modern Organic Synthesis

SPONSOR

 

 

BioFuture 2026 (October 27–28 in New York City) is two days of programming that tackles what biopharma is actually working through: funding gaps, policy shifts, AI convergence. 500+ global attendees tackle the industry's hardest questions and build the relationships that move their companies forward. More at https://biofuture.com.

FEATURED ARTICLE

Connect The Dots: Precision Testing Leads To Patient Access In Oncology

Precision oncology only works when effective biomarker testing helps identify the right patients before launch, explains Boehringer Ingelheim’s Vicky Brown.

 

INDUSTRY INSIGHTS

 

Corticosteroids And Hormonal Therapies — History, Use, And Future Outlook

Explore how evolving science, expanding global demand, and next-generation innovations are reshaping the future of corticosteroid and hormonal therapies — and what this transformation means for the years ahead.

 

A Strategic Guide To FSP Models In Clinical Development

Ready to scale your clinical trials without sacrificing quality? Explore a practical framework for building flexible, high-capacity partnerships across the development lifecycle.

 

From Disconnected Data To AI-Ready Manufacturing

Disconnected manufacturing data limits quality and AI readiness. A connected IT/OT foundation helps teams reduce downtime, improve QC speed, and turn production data into trusted intelligence.

 

EMPQ In New Facilities: An Industry-Harmonized Approach

Harmonized approaches streamline facility qualification. This guide shares best practices for EMPQ, promoting consistency, compliance, and readiness in new facilities.

 

Five Of The Most Useful Transformations In Modern Organic Synthesis

The five reactions commonly used in medicinal chemistry are a mix of “traditional” reactions and newer transformations that all share a high level of robustness and flexibility.

 

How To Accelerate Early-Phase Oncology Trial

Purpose-built early-phase oncology sites can enroll patients within 7–10 days post-activation while maintaining quality and diversity; academic centers often lag due to complexity and saturation.

 

Improving The Patient Experience In Clinical Research

To preserve the quality of care and build a more effective approach to trial design, a sponsor must consider their approach to patient recruitment and enrollment early and often.

Connect With Life Science Leader: